HomeOpen Access NewsAutoimmune diseases

autoimmune diseases

Addressing the needs of people living with autoimmune conditions

Asal Shirazi, Founder and CEO of the Autoimmune Support and Awareness (ASA) Foundation, explains the challenges in detecting, diagnosing and managing autoimmune conditions.

Immunocompromised patients show low immune response after second vaccine

According to the OCTAVE study, immunocompromised patients presented low immune responses after two doses of the same COVID-19 vaccine.

Clinical trial to test third COVID-19 vaccine for people with weakened immune systems

A new clinical trial will investigate whether a third COVID-19 vaccine dose gives a stronger immune response for people with weakened immune systems.

Campaigners call for approval of life saving COVID-19 antibody treatments

A group of patient bodies, charities and senior clinicians have urged the Government to approve the use of life-saving COVID-19 antibody treatments.

Immune system research: Vaccines and immunotherapeutics

Dr Babita Agrawal, Professor at the University of Alberta, discusses both the vital present and future roles of vaccines and immunotherapeutics in combatting COVID-19.

Curative approach to severe autoimmune diseases

Andrew Mackie, VP Business Development tells us how Imcyse, a Belgian immunotherapy expert, seeks a curative approach to severe autoimmune diseases.

Childhood trauma linked to multiple sclerosis development

Scientist have found that childhood trauma could affect the development and treatment of multiple sclerosis in adulthood.

Scientists use immune system to predict likelihood of long COVID

Cambridge researchers have published their findings on how the immune system could be an early clue for the later development of severe or long COVID.

The beginning of the end for Type 1 diabetes: A new view from immunotherapy science

Jean Van Rampelbergh PhD, VP Clinical & Regulatory at Imcyse SA, introduces ImotopesTM a cutting-edge immunotherapy science with an excellent safety profile that could cure Type 1 diabetes or drastically change treatment options.

Rethinking Type 1 diabetes with a radically new immunotherapy approach

Jean Van Rampelbergh PhD, VP Clinical & Regulatory at Imcyse SA, introduces Imotopes™, the innovative new immunotherapy approach causing scientists to rethink Type 1 diabetes and its treatment.

Advertisements


Latest Academic Articles

The latest academic articles from key research stakeholders